UK Biobank, the world’s most significant source of data and biological samples for health research, is set to receive £127.6m to fund a move to a larger, faster, and more efficient, purpose-built facility at Bruntwood SciTech’s Manchester Science Park. This follows an application by the Medical Research Council to the UK Research and Innovation (UKRI) Infrastructure Fund to support UK Biobank’s development.
Professor Dame Ottoline Leyser, CEO of UKRI, said: “UKRI is proud to invest in cutting-edge infrastructure across the UK to drive discovery, strengthen innovative businesses and improve public services, creating a wide range of high-quality jobs. UK Biobank is one of the UK’s leading biomedical science infrastructures, providing essential resources for thousands of academic and industry projects in the UK and around the world. Demand is growing year-on-year as UK Biobank’s datasets get richer over time. The insights enabled by UK Biobank have already driven change in the NHS and we look forward to seeing this powerful resource continue to thrive.”
UK Biobank’s biological samples, laboratories, headquarters and around half of its 250 staff will move to the new facility. The funding will cover a latest-generation robotic freezer that stores and retrieves 20 million biological samples that have been donated by UK Biobank’s 500,000 volunteer participants. The facility will enable new projects to turn the samples into data and drive discoveries into how to prevent and treat a wide range of diseases.
With the support of the University of Manchester, Bruntwood SciTech – one of the UK’s leading property developers dedicated to the growth of the science and technology sector – is developing the new 131,000 sq ft Greenheys facility within Manchester Science Park, which sits at the heart of the city’s Oxford Road Corridor innovation district.
Professor Dame Nancy Rothwell, President and Vice-Chancellor of the University of Manchester and member of UK Biobank’s Board, said: “I’m very pleased that UK Biobank has chosen to move here as it is yet more evidence of how Manchester has become one of the world’s leading hubs for science and innovation. UK Biobank will be joining the community of stellar research organisations that are already working with the University of Manchester to make a difference across the UK and around the world.”
Professor Dame Nancy Rothwell, President and Vice-Chancellor of the University of Manchester and member of UK Biobank’s Board
Kath Mackay, Director of Life Sciences at Bruntwood SciTech, said: “Manchester is a world-renowned hub for science and technology, and the ability for UK Biobank to grow here is testament to the quality of talent, innovation and support within the city. The development of Greenheys represents the third phase of our masterplan to grow Manchester Science Park to more than 1 million sq ft of cutting-edge life sciences and tech space which, critically, will support the creation of over 2,500 jobs as Manchester’s Oxford Road Corridor continues to thrive.”
Kath Mackay, Director of Life Sciences at Bruntwood SciTech
Relocation to the Greenheys site on Manchester Science Park will provide UK Biobank with new opportunities for collaboration with multi-disciplinary researchers and industry. It will also offer access to additional talent due to the proximity to leading institutions operating across research, academia, business and the NHS.
The move will also support the Government’s ambitions stated in the ‘Levelling Up’ White Paper to increase R&D spending outside the Greater Southeast by over 40% by 2030, whilst retaining UK Biobank in the Greater Manchester area and contributing to the advancement of one of the UK’s most established life science and tech communities.
Over the next decade, UKRI’s infrastructure funding will support:
- Development of the new purpose-built facility at Manchester Science Park UK Biobank will occupy three floors of a new building, which will house upgraded biological sample storage, processing laboratories and offices. The facility is expected to break ground in Autumn 2023 and be operational in 2026, subject to planning permission.
- Replacement of UK Biobank’s ageing infrastructure Modern robotic storage archives for UK Biobanks 16 million biological samples will provide future capacity for sample collections, improve speed of sample retrieval fourfold, and improve environmental efficiency.
- Enhancement of UK Biobank’s data assets to broaden the dataset and improve tools for researchers and industry. This will include linking to further health records and socio-economic and environmental data. UK Biobank will be able to take advantage of public, philanthropic and industry investment to undertake new sample collections, assays and other enhancements, having previously been constrained by outdated infrastructure.
- New links with Manchester’s life and data sciences enterprise system Given the proximity to the University of Manchester and its strength in growth areas including AI, diagnostics, digital and biotechnology, the relocation will bring opportunities for UK Biobank and the University to stimulate innovation, health impact and economic growth. This partnership will also be pivotal to the local, regional and national life sciences ecosystem and the presence of their research and IP will help foster new treatments and cures.
- Development of a ‘Hub’ to engage with new and existing collaborators This new location will help to promote academic, commercial and public health links in the Manchester region and beyond. With a particular focus on start-up and SME engagement, generation of intellectual property will be encouraged by collaboration between UK Biobank, the University of Manchester, Bruntwood SciTech and its customers and the NHS.
Michael Dunn, Director of Discovery Research at Wellcome said: “In particular, the new investment in a purpose-built facility for UK Biobank, which Wellcome has co-funded since its inception, will ensure it remains a world-leading centre of biomedical science, serving as a vital resource for researchers globally.”
Prof Sir Rory Collins, Principal Investigator and CEO of UK Biobank, said: “We are thrilled to be moving to a world-leading centre for genomics and data, where we can build on existing relationships with The University of Manchester. We are incredibly grateful to UKRI for their funding and support, which will enable us to consider new ways to enrich the data and make UK Biobank even more valuable for health research. The improved technologies and capacity at our new home will also make it quicker and easier for researchers from around the world to conduct vital research into common and life-threatening diseases and enable new scientific discoveries that improve human health.
The new scheme is subject to planning approval by Manchester City Council. UK Biobank’s relocation is supported by Arcadis, the global built environment consultancy and Metro-Dynamics, the economics consultancy. Bruntwood SciTech’s facility design team is led by BDP Manchester with Silcock Leedham, DW Consulting, Walker Sime and Deloitte.